Table 1 presents the main categories of NaV1.4 skeletal muscle channelopathies, describes the clinical phenotypes, triggers, NaV1.4 mutations and newly identified pathogenic mutations, as well as the clinically preferred therapeutic agents associated with muscle disorders. This evidence concerns the gene SCN4A and muscular disease.